Ten-year Follow-up of a Prospective, Randomized Trial of BT563/BB10 Versus Anti-thymocyte Globulin as Induction Therapy After Heart Transplantation

Interleukin-2 Receptor Antagonists as Induction Therapy After Heart Transplantation: Systematic Review With Meta-Analysis of Randomized Trials

“…The IL-2Ra used was daclizumab in 3 trials, 16 -18 basiliximab in 4 trials 19 -22 and BT563 in 2 trials. 23,24 Baseline immunosuppressive therapy was the same within trials, but varied among the trials. Cyclosporine and steroids were used in all trials.…”

Antithymocyte globulin induction therapy for adult heart transplantation: A UK national study

“…They also reported that the ATG group had a higher incidence of viral infection, although the overall infection rates were similar, and patients in the ATG group were more likely to be free from cardiac allograft vasculopathy. 7,14,17 In contrast, the ISHLT registry reported that patients monitored for 1 year who received no induction therapy were less likely to experience a treated rejection episode than those treated with polyclonal anti-thymocyte induction therapy (21% vs 24%, p Ͻ 0.001). 16 Mycophenolate use was higher in the ATG group.…”

“…7 Some institutions use biologic induction agents, including ATG, muromonab-CD3, or a monoclonal antibody against the interleukin IL-2 receptor (IL-2R), with the aim of (1) delaying the introduction or reducing the dose of cyclosporine or tacrolimus, thereby reducing nephrotoxicity 8,9 ; (2) achieving more robust immunosuppression during the early postoperative period 10 ; and (3) reducing or delaying the incidence of acute rejection. 8,11 Although there have been a number of studies of ATG as an induction agent, [12][13][14][15] none of these investigations have been in the form of placebo-controlled trials.…”

Clinical Outcome and Life Quality of Patients After Monophasic Encephalitis

“…In a trial comparing 2 different agents for in-duction immunosuppression in heart transplant recipients, the dosage was tapered to 0.1 mg/kg per day on the second month. 8 Another similar trial reported prednisone dosages of 0.25 mg/kg per day at 1 month tapered to 0.2 mg/kg per day on the third month. 11 One single-center report uses rabbit anti-thymocyte globulin induction and a prednisone taper starting at 0.4 mg/kg per day and tapered to 0.2 mg/kg per day on the third month and 0.1 mg/kg per day on the sixth month.…”